CAGT hero 2

Leaders in Developing and Applying Genomic Technologies

The Genomic Revolution promises the discovery of targeted approaches for treating disease. Innovations like CRISPR-based genome editing and comprehensive epigenomic profiling can inform, streamline and accelerate drug target discoveries, but piecing together this complex puzzle requires an interdisciplinary approach.

The Center for Advanced Genomic Technologies (CAGT) has assembled a team of world-leading engineers, scientists and physicians to integrate these technologies to unravel disease biology and discover new drug targets. By working together, we will catalyze a more robust biotechnology enterprise.

In the News

Charlie Gersbach, Greg Crawford, Tim Reddy, Andrew Allen, David Page, Sayan Mukherjee

September 9, 2021

Two new NIH-funded centers to explore impacts of genomic variation in health, disease

Duke University is the recipient of two large grants totaling nearly $12 million from NHGRI.

PDX1 immunostaining of liver tissue sections at 14 d after injection of mice treated with control and Pdx1-targeted gRNAs. Scale bars, 50 µm.

August 2, 2021

New Mice Enable CRISPR-based Epigenome Editing in Living Animals

A CRISPR-Cas9 variant with deactivated DNA-cutting function – known as “dCas9” - is a powerful tool to help researchers understand what genes do when their expression is dialed up or down, but it has some limitations.